Cosciens Biopharma Files March 2025 6-K Report
Ticker: CSCIF · Form: 6-K · Filed: Mar 13, 2025 · CIK: 1113423
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, company-name-change
TL;DR
Cosciens Biopharma filed its March 6-K, standard foreign issuer update.
AI Summary
Cosciens Biopharma Inc. filed a Form 6-K on March 13, 2025. The filing is a report of a foreign private issuer for the month of March 2025. The company's principal executive office is located in Toronto, Ontario, Canada. Cosciens Biopharma Inc. previously operated under the names Aeterna Zentaris Inc. and Aeterna Laboratories Inc.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Cosciens Biopharma's status as a foreign private issuer.
Risk Assessment
Risk Level: low — This filing is a routine report and does not contain new material financial or operational information that would typically increase risk.
Key Players & Entities
- COSCIENS Biopharma Inc. (company) — Filer
- Aeterna Zentaris Inc. (company) — Former company name
- AETERNA LABORATORIES INC (company) — Former company name
- Norton Rose Fulbright Canada, LLP (company) — Legal counsel/address provider
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, providing information that the issuer makes or is required to make public in its home country.
When was this Form 6-K filed?
This Form 6-K was filed on March 13, 2025.
What is the company's current name?
The company's current name is COSCIENS Biopharma Inc.
What were the company's former names?
The company was formerly known as Aeterna Zentaris Inc. and Aeterna Laboratories Inc.
Where is the company's principal executive office located?
The company's principal executive office is located at c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 13, 2025 regarding COSCIENS Biopharma Inc. (CSCIF).